All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MDS Hub

MDS Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
Add bookmark

Cumulative thrombotic risk between CALR1, CALR2 and JAK2V617F mutations in ET

Here, we summarize a systematic review and meta-analysis by Neupane et al. comparing cumulative thrombotic risk between CALR1-, CALR2-, and JAK2V617F-mutated ET.

Dec 6, 2023
Add bookmark

The role of AI in the future of MPN bone marrow histopathology

The MPN Hub invited Daniel Royston, University of Oxford, UK, to give a presentation and chair a discussion on the role of artificial intelligence in the future of MPN bone marrow...

Dec 4, 2023
Add bookmark

ASH2023 abstracts: What’s hot in MPN?

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN.

Dec 4, 2023
Add bookmark

Thrombotic and hemorrhagic complications in MPN

Thrombotic and hemorrhagic complications in MPN

Nov 30, 2023
Jean-Jacques Kiladjian

"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You are sure to find a response to your burning questions about MPN here!"

Jean-Jacques Kiladjian

"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You are sure to find a response to your burning questions about MPN here!"

Featured Expert Opinion

Add bookmark

What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?

During the #ASCO23 Annual Meeting, the MPN Hub was pleased to speak to Helen...

Myelofibrosis Clinical Trial Club

view more

Polycythemia vera

view more

Most Read

Essential thrombocytosis

view more

Most Viewed